Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of year two data from AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis (RA) Subjects With ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

Standing toe-to-toe with giants is nothing to sniff at, but bagging an outright advantage is something else: Just ask Eli Lilly's Taltz, which notched a head-to-head victory against AbbVie's behemoth ...

The first of at least 8 adalimumab biosimilars has finally launched in the United States after being kept off the market for years due to settlement agreements with the maker of the reference product, ...

Please provide your email address to receive an email when new articles are posted on . Simlandi (adalimumab-ryvk) hit the market as first interchangeable, citrate-free Humira biosimilar in a ...

Please provide your email address to receive an email when new articles are posted on . Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just ...

Alvotech (NASDAQ:ALVO) and partner Teva Pharmaceuticals (NYSE:TEVA) announced Friday the U.S. Food and Drug Administration (FDA) approval for their arthritis injection, Simlandi (adalimumab-ryvk).

INDIANAPOLIS, June 14, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study in ...

Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...

A long-awaited moment for consumers arrived last year when patent protection expired on the nation’s most prescribed medicine, AbbVie’s wildly successful — and costly — rheumatoid arthritis drug ...